Denice Torres - 25 Jun 2026 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Reporting relationship: Director
Issuer ticker: CLDX
Reported as of: 25 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jun 2026, 16:12:40 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sam Martin, attorney-in-fact for Denice Torres

Key filing fact

Denice Torres filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 29 Jun 2026.

Key facts

This page summarizes Denice Torres's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Jun 2026, 16:12.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001820278 Primary reporting owner

Relationship: Director
Address: C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON
Signature: /s/ Sam Martin, attorney-in-fact for Denice Torres
Signature date: 29 Jun 2026

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLDX transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.